Tender Details

Country: USA
Summary: Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
UST Ref No: 121732226
Deadline: 11 Jul 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 75A50125R00006
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
Synopsis
This pre-solicitation notice serves as the intent to announce a Request for Proposal (RFP) at a later date for the advanced development, licensure, and procurement of vaccines against Marburg virus (MARV) and Sudan ebolavirus (SUDV). Furthermore, the intended RFP will also support late-stage development and Phase 4 Post-Marketing commitments/requirements required by the Food and Drug Administration (FDA) for products approved under the animal rule.
The Filovirus family, which includes Marburg virus (MARV) and the ebolaviruses Ebola virus (EBOV) and Sudan virus (SUDV), are known to cause severe health consequences, including death, in humans. Infections with EBOV, SUDV, and MARV can lead to case fatality rates of up to 90%. The West Africa outbreak of EBOV during 2014-2016 resulted in 28,646 confirmed, probable, and suspected cases, with 11,323 reported deaths. Several individuals were transported back to the US for treatment, and four confirmed cases were treated in the US, underscoring the urgent need for medical countermeasures (MCMs) for filoviruses to be developed, manufactured, and stockpiled to protect the US population. While there is a licensed vaccine against EBOV, there are currently no FDA-licensed vaccines or therapeutics for SUDV and MARV. The immediate need for MARV and SUDV vaccines has been emphasized by recent outbreaks, including the SUDV outbreak in 2022 that resulted in 141 confirmed cases and 55 deaths. Additionally, a MARV outbreak in 2024 led to 66 confirmed cases and 15 deaths.
In 2006, the Department of Homeland Security (DHS) determined that Ebola virus and MARV are material threats to national health security. The threat of filovirus agents being used as biological/bioterror weapons led the DHS to issue a Material Threat Determination (MTD) based on its Material Threat Assessment (MTA) for Ebola virus and MARV.
Based on an assessment by DHS and medical consequence monitoring by the Department of Hea...
Documents:

Pre-Solicitation-Notice-75A50125R00006.pdf

If you are registered member, kindly login to view full details of this tender notice:

Marburg virus (MARV) and Sudan virus (SUDV) Vaccines - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE, a Government sector organization in USA, has announced a new tender for Marburg virus (MARV) and Sudan virus (SUDV) Vaccines. This tender is published on USARFP under UST Ref No: 121732226 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-07-11.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.